Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.9K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.7K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

206
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
206

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Assisted Screening for Patients With Diabetic Retinopathy and Age-Related Macular Degeneration in Family Medicine and Geriatric and Gerontology Care: Protocol for a Pragmatic Randomized Clinical Trial.

JMIR research protocols·2026
Same author

"That's not my silo": Navigating fragmented long COVID care in the mid-Atlantic United States.

SSM. Qualitative research in health·2026
Same author

Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations.

Hepatology communications·2026
Same author

Flowing differently: exploratory characterization of menstrual effluent compared with peripheral blood.

F&S science·2026
Same author

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia.

Gut·2026
Same author

5' leader defects drive persistent HIV-1 viremia on long-term ART.

Nature communications·2026

Related Experiment Video

Updated: Dec 14, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.2K

Progress towards elimination goals for viral hepatitis.

Andrea L Cox1, Manal H El-Sayed2, Jia-Horng Kao3,4

  • 1Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. acox@jhmi.edu.

Nature Reviews. Gastroenterology & Hepatology
|July 25, 2020
PubMed
Summary

Experts question the feasibility of eliminating viral hepatitis by 2030, citing progress gaps. The focus remains on hepatitis B virus and hepatitis C virus elimination strategies for the next decade.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.8K

Related Experiment Videos

Last Updated: Dec 14, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.2K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.8K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health Policy

Background:

  • Viral hepatitis, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV), represents a significant global health burden, comparable to HIV, malaria, and tuberculosis in mortality.
  • The World Health Organization set a goal in 2016 for Member States to eliminate viral hepatitis as a public health threat by 2030.

Purpose of the Study:

  • To assess the feasibility of achieving viral hepatitis elimination by the 2030 target.
  • To identify key areas of progress and critical focus points for viral hepatitis elimination efforts over the next decade and beyond.

Main Methods:

  • A viewpoint piece soliciting opinions from leading scientists and clinicians in the viral hepatitis field.
  • Analysis of current policy and progress in relation to the 2030 elimination goal.

Main Results:

  • While progress has been made, significant policy and implementation gaps persist, raising questions about the attainability of the 2030 deadline.
  • Expert opinions highlight the need for sustained focus and strategic interventions to bridge these gaps.

Conclusions:

  • Achieving viral hepatitis elimination by 2030 faces considerable challenges, necessitating a re-evaluation of strategies and intensified efforts.
  • Continued research, policy development, and clinical advancements are crucial for the long-term goal of viral hepatitis eradication.